Swiss drugs ­industry supplier Lonza Group said it was building a new facility in Singapore to expand its cell therapy business. Lonza said that the total investment for the first phase would be approximately 30 million Swiss francs ($27.03 million). Construction is due to begin in early 2010 and the facility is expected to be operational by mid-2011, it added. "The facility will operate with cutting-edge technologies and a skilled labor force, allowing it to readily meet the needs of a broad range of customers and address the growing global demand for Cell Therapies," said Lonza CEO Stefan Borgas in a statement.